Clinical experience of a long-acting pegylated erythropoietin-stimulating agent in pediatric chronic kidney disease

Bantounou, Maria Anna and Lamb, Angela and Young, David and Ramage, Ian James and Reynolds, Ben Christopher (2023) Clinical experience of a long-acting pegylated erythropoietin-stimulating agent in pediatric chronic kidney disease. The Journal of Pediatric Pharmacology and Therapeutics, 28 (6). pp. 509-518. ISSN 1551-6776 (https://doi.org/10.5863/1551-6776-28.6.509)

[thumbnail of Bantounou-etal-JPPT-2023-Clinical-experience-of-a-long-acting-pegylated-erythropoietin-stimulating-agent-in-pediatric-chronic-kidney-disease] Text. Filename: Bantounou-etal-JPPT-2023-Clinical-experience-of-a-long-acting-pegylated-erythropoietin-stimulating-agent-in-pediatric-chronic-kidney-disease.pdf
Accepted Author Manuscript
Restricted to Repository staff only until 5 December 2024.
Download (556kB) | Request a copy

Abstract

OBJECTIVE Management of anemia of chronic kidney disease (CKD) often includes subcutaneous or intravenous administration of erythropoietin-stimulating agents (ESAs). Mircera, a pegylated continuous erythropoietin receptor agonist, has a longer duration of action and requires less frequent administration than other ESAs. Pediatric experience with Mircera is limited. We retrospectively reviewed our long-term experience of Mircera in a national pediatric nephrology center. METHODS Patients were identified via an electronic patient record database. Data collected included demographics (sex, age, etiology of CKD, CKD stage, dialysis modality), dosing information, and laboratory data—hemoglobin (Hb), parathormone (PTH), ferritin, hematinics prior to commencing Mircera and all subsequent values associated with dose adjustments. RESULTS Seventy-seven patients aged 2 to 18 years, with CKD stages 2 to 5T had received at least 1 dose of Mircera, with 75 patients having sufficient data and a total of 1473 doses. No patients discontinued Mircera owing to adverse effects. One patient experienced a potential severe adverse drug reaction. Mircera was effective in improving or maintaining Hb ≥10.0 g/dL in most (58/75, 77.3%) patients. The median dose to achieve Hb ≥10.0 g/dL was 2.1 µg/kg/4 wk. Most doses (1039, 71.5%) were administered 4-weekly. The doses (161, 11.1%) that were administered 6-weekly remained efficacious. Thirty-two patients started Mircera with Hb <10.0 g/dL; 26 (81%) achieved Hb ≥10.0 g/dL within a median time of 4 months. Mircera was less effective if given every 8 weeks, or in the presence of hyperparathyroidism or hyperferritinemia. CONCLUSION Mircera appears safe and effective in pediatric patients with CKD.

CORE (COnnecting REpositories)